Skip to main content
. 2019 Jan 11;98(2):e14022. doi: 10.1097/MD.0000000000014022

Figure 3.

Figure 3

Comparison of SUVmax depending on the presence of medial foot pain, treatment modalities, and subtypes. (A) The SUVmax in symptomatic ANBs (n = 49, SUVmax = 8.51 ± 1.16 g/mL) was significantly higher than that in asymptomatic ANBs (n = 99, SUVmax = 2.48 ± 0.19 g/mL) (P < .001). (B) The SUVmax was significantly different according to the treatment modalities (P < .001): the SUVmax of surgically resected ANBs (n = 12, SUVmax = 11.11 ± 2.79 g/mL) was significantly higher compared to that of ANBs that were only observed (n = 113, SUVmax = 3.22 ± 0.38 g/mL) and the SUVmax of the conservative treatment group (n = 23, SUVmax = 7.18 ± 1.40 g/mL) (P < .05). ANBs with conservative treatment also showed higher SUVmax than those in the observation only group (P < .05). (C) Subtype II-1 ANBs had significantly greater SUVmax (n = 31, SUVmax = 9.63 ± 1.68 g/mL) than subtype II-0 ANBs (n = 58, SUVmax = 4.27 ± 0.50 g/mL) (P < .001). Data = mean ± standard error of the mean. ANB = accessory navicular bone, SUVmax = maximum standardized uptake value. ∗P < .001 and ∗∗P < .05.